Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

Abstract

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

1 .- 33 . (canceled) 
     
     
         34 . A method of treating a HER2-positive cancer patient comprising administering to the patient an initial dose of 840 mg of Pertuzumab followed every 3 weeks thereafter by a dose of 420 mg of Pertuzumab, and further comprising re-administering an 840 mg dose of Pertuzumab to the patient if the time between two sequential 420 mg doses is 6 weeks or more. 
     
     
         35 . The method of  claim 34 , further comprising administering 420 mg of Pertuzumab every 3 weeks after the re-administered 840 mg dose. 
     
     
         36 . The method of  claim 34 , wherein the cancer patient has HER2-positive breast cancer. 
     
     
         37 .- 42 . (canceled)